WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012054333) METHODS FOR IDENTIFYING INHIBITORS OF ABETA42 OLIGOMERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/054333    International Application No.:    PCT/US2011/056349
Publication Date: 26.04.2012 International Filing Date: 14.10.2011
IPC:
G01N 33/53 (2006.01)
Applicants: MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 (US) (For All Designated States Except US).
ZHAO, Wei-Qin [US/US]; (US) (NZ, US only).
MCCAMPBELL, Alexander [US/US]; (US) (NZ, US only).
RAY, William, J. [US/US]; (US) (NZ, US only).
TOOLAN, Dawn, M. [US/US]; (US) (NZ, US only)
Inventors: ZHAO, Wei-Qin; (US).
MCCAMPBELL, Alexander; (US).
RAY, William, J.; (US).
TOOLAN, Dawn, M.; (US)
Common
Representative:
MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 (US)
Priority Data:
61/394,854 20.10.2010 US
Title (EN) METHODS FOR IDENTIFYING INHIBITORS OF ABETA42 OLIGOMERS
(FR) PROCÉDÉS D'IDENTIFICATION D'INHIBITEURS D'OLIGOMÈRES ABÊTA42
Abstract: front page image
(EN)The invention herein is directed to immunoassays for the detection of Αβ42 oligomers. The inventive assays are based on the observations herein that the presence of Αβ42 oligomers in a preparation is directly related to a decrease in a C-terminal (CT) immunosignal and a correlated increase in an N-terminal (NT) immunosignal, relative to the immunosignal generated in the absence of Αβ42 oligomers, in an Αβ42 CT and NT ELISA assay and an Αβ42 CT AlphaLISA assay. The invention herein involves the use of these assays alone or in combination to screen for inhibitors of Αβ42 oligomerization.
(FR)La présente invention concerne des immunodosages destinés à la détection d'oligomères Αβ42. Les dosages de l'invention sont basés sur les observations selon lesquelles la présence d'oligomères Αβ42 dans une préparation est directement liée à une diminution d'un immunosignal C-terminal (CT) et à une augmentation corrélée d'un immunosignal N-terminal (NT), par rapport à l'immunosignal produit en l'absence d'oligomères Αβ42, dans un dosage CT Αβ42 et NT ELISA et un dosage AlphaLISA CT Αβ42. L'invention implique l'utilisation de ces dosages seuls ou en association, afin de cribler des inhibiteurs de l'oligomérisation Αβ42.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)